Literature DB >> 18400544

The antibacterial activity against MRSA strains and other bacteria of a <500Da fraction from maggot excretions/secretions of Lucilia sericata (Diptera: Calliphoridae).

Alyson Bexfield1, A Elizabeth Bond, Emily C Roberts, Edward Dudley, Yamni Nigam, Stephen Thomas, Russell P Newton, Norman A Ratcliffe.   

Abstract

The application of Lucilia sericata larvae to chronic, infected wounds results in the rapid elimination of infecting microorganisms, including MRSA. Previously, we demonstrated in vitro antibacterial activity of native excretions/secretions (nES) from L. sericata and partially purified two low mass antibacterial compounds with masses of 0.5-10kDa and <500Da. The present study reports the antibacterial effects of the <500Da fraction (ES<500) on the growth and morphology of a range of bacteria, including 12 MRSA strains. Distinct morphological changes were observed in Bacillus cereus and Escherichia coli following exposure to ES<500. Flow cytometry and confocal microscopy analyses, in conjunction with turbidometric and CFU assays, revealed bacteriostatic activity of nES against S. aureus and E. coli. ES<500 also demonstrated bacteriostatic activity against S. aureus, however, bactericidal activity and the induction of a viable but non-culturable state were observed with ES<500-treated E. coli.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18400544     DOI: 10.1016/j.micinf.2007.12.011

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  19 in total

Review 1.  TIME management by medicinal larvae.

Authors:  David I Pritchard; Václav Čeřovský; Yamni Nigam; Samantha F Pickles; Gwendolyn Cazander; Peter H Nibbering; Anke Bültemann; Wilhelm Jung
Journal:  Int Wound J       Date:  2015-07-15       Impact factor: 3.315

2.  Lucilia sericata chymotrypsin disrupts protein adhesin-mediated staphylococcal biofilm formation.

Authors:  Llinos G Harris; Yamni Nigam; James Sawyer; Dietrich Mack; David I Pritchard
Journal:  Appl Environ Microbiol       Date:  2012-12-07       Impact factor: 4.792

Review 3.  Maggot therapy takes us back to the future of wound care: new and improved maggot therapy for the 21st century.

Authors:  Ronald A Sherman
Journal:  J Diabetes Sci Technol       Date:  2009-03-01

4.  Immunomodulatory potential of black soldier fly larvae: applications beyond nutrition in animal feeding programs.

Authors:  Elizabeth Koutsos; Bree Modica; Tarra Freel
Journal:  Transl Anim Sci       Date:  2022-06-22

5.  A novel approach to the antimicrobial activity of maggot debridement therapy.

Authors:  Anders S Andersen; Dorthe Sandvang; Kirk M Schnorr; Thomas Kruse; Søren Neve; Bo Joergensen; Tonny Karlsmark; Karen A Krogfelt
Journal:  J Antimicrob Chemother       Date:  2010-06-11       Impact factor: 5.790

6.  Lucifensin, the long-sought antimicrobial factor of medicinal maggots of the blowfly Lucilia sericata.

Authors:  Václav Cerovský; Jan Zdárek; Vladimír Fucík; Lenka Monincová; Zdenek Voburka; Robert Bém
Journal:  Cell Mol Life Sci       Date:  2009-11-18       Impact factor: 9.261

7.  Quorum-sensing-regulated virulence factors in Pseudomonas aeruginosa are toxic to Lucilia sericata maggots.

Authors:  A S Andersen; B Joergensen; T Bjarnsholt; H Johansen; T Karlsmark; M Givskov; K A Krogfelt
Journal:  Microbiology (Reading)       Date:  2009-11-05       Impact factor: 2.777

8.  Selection and Evaluation of Tissue Specific Reference Genes in Lucilia sericata during an Immune Challenge.

Authors:  Andre Baumann; Rüdiger Lehmann; Annika Beckert; Andreas Vilcinskas; Zdeněk Franta
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

9.  Lucifensins, the Insect Defensins of Biomedical Importance: The Story behind Maggot Therapy.

Authors:  Václav Ceřovský; Robert Bém
Journal:  Pharmaceuticals (Basel)       Date:  2014-02-27

Review 10.  Mechanisms of maggot-induced wound healing: what do we know, and where do we go from here?

Authors:  Ronald A Sherman
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-13       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.